OCT 29 - 30 2014
Cancer: Research, Discovery and Therapeutics
43 39 91763

BioConference Live makes it easier and more cost-effective for the cancer research community to come together online through live video webcasts and real-time networking. BioConference Live attendees learn new concepts, tools and techniques that they can apply to research and diagnosis. BioConference Live requires no travel or time away from the lab or hospital, yet delivers all the benefits of a physical conference. Attendees can earn free CME and CE Credits.

Topics will include Drug Discovery, Clinical Proteomics, Molecular Profiling, Cancer Metabolism: Nutrition and Cancer, Cancer Epigenetics, Therapeutics, Novel trends in cancer detection and screening, Immunotherapy/Harnessing the Immune System for Cancer Therapy, Noninvasive molecular screening for colon cancer, Biomarkers in prostate and bladder cancer, Animal mouse models, Cell signaling, Resistance due to mutations, Kinome profiling, Individualized patient diagnostics, Cancer Therapies & new techniques, Diagnostic testing for clinical decision, Best practices for pregnancy testing prior to cancer therapy, Lactogenic anemia and diagnostic testing: tools for blood conservation in cancer patients and other frail patient, High Dose IL-2 -curative therapy for Metastatic Renal Cell Carcinoma, and other topics.

This event will bring together research scientists, post docs, principal investigators, lab directors and professionals from around the world to learn about recent advances in cancer research. This conference offers an amazing opportunity as it is free to participants, and there will be no out-of-pocket expenses for travel. However, participants will still benefit from interacting with a global community of like-minded colleagues, without leaving the comfort of their office or home.

Conference participants will be able to
 

  • Attend interactive live streaming video sessions
  • Have their questions answered in real-time by industry experts
  • Chat live with peers and speakers
  • Browse a virtual exhibit floor for solution providers


No crowded airports, delayed flights or expensive hotel rooms, but still the look and feel of a first-rate conference with world renowned experts. Participants also benefit from the fact that experts and vendors are more accessible, no more waiting in line to speak to someone. Think it is too good to be true? Checkout the venue and become a believer.


Speakers:
  • Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University
  • Senior Lecturer, School of Biomolecular & Biomedical Science, Co-Director, Cancer Biology & Therapeutics Laboratory, University of Dublin
  • Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy
  • Chief Science Officer, Cynvenio
  • Deputy Director of Basic Science, Professor and Director Integrated Cancer Genomics Division, TGen
  • Group Leader - Clinical Proteomics, Cancer Research Technology Program (CRTP), Frederick National Laboratory for Cancer Research (FNL), Leidos Biomedical Research, Inc.
  • Assistant Professor, Biomedical Diagnostic & Therapeutic Sciences, , Oakland University
  • Scientist BC Cancer Agency's Deeley Research Centre, Assistant Professor Department of Biochemistry and Microbiology, University of Victoria
  • Principal Investigator, Metallo Lab, Assistant Professor, Bioengineering, University of California, San Diego
  • Director, Clinical Analytics and Workflow Products, CLC Bio, a Qiagen company
  • Associate Professor of Biomedical Engineering, University of Virginia
  • Head, Computational Structural Biology Group, Senior Investigator, Center for Cancer Research, National Cancer Institute
  • Associate Professor of Pathology, Clinical Toxicology, Director, Point-of-Care Testing, Johns Hopkins University School of Medicine
  • Chief, Pathology at Lucile Packard Children's Hospital at Stanford, Associate Professor in the Department of Pathology, Stanford University
  • Chief Scientific Officer at OncoMark, Professor of Cancer Biology, University of Dublin
  • Senior Market Manager, Oncology , Illumina
  • Associate Professor, Neuro-Oncology Research, Barrow Brain Tumor Research Center, Barrow Neurological Institute
  • Director, NSF IGERT Nanomedicine Science and Technology Program, Director, Electronic Materials Research Institute, Arts and Sciences Distinguished Professor of Physics, Lecturer on Radiation
  • Principal Investigator, Structure and Function of the Cell Nucleus research unit, Full Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Instit
  • Senior Scientist, Product Development, Qiagen
  • Associate Professor, University of Victoria
  • Assistant Professor, Nutrition, UNC Gillings School of Global Public Health
  • Assistant Professor, Cancer Biology , City of Hope National Medical Center
  • Research & Development Scientist, Thermo Fisher Scientific
  • Director, Head of Biological research content, Qiagen, Inc.
  • Co-Director, Complex Adaptive Systems Initiative, Director, Transformative Healthcare Networks, Professor, School of Life Sciences, Arizona State University (ASU)
  • Professor of Genome Sciences, University of Washington, School of Medicine
  • Business Unit Management, Senior Business Unit Manager, The Jackson Laboratory
  • Chief Scientific Officer, XTuit Pharmaceuticals, Inc.
  • Associate Professor of Surgery, Division of Adult Cardiothoracic Surgery, Chief of General Thoracic Surgery, University of California, San Francisco, VA Medical Center
  • Clinical Research Product Manager, DNASTAR
  • Head, Synthetic Biologics Core, Cancer and Inflammation Program, Center for Cancer Research National Cancer Institute

Show Resources
Agenda
All times are Pacific Time
  • OCT 29, 2014 06:00 AM PDT
    Speaker: Kelli Bramlett, M.S.
  • OCT 29, 2014 06:00 AM PDT
    Speaker: Srinivas (Sri) Sridhar, PhD
  • OCT 29, 2014 07:30 AM PDT
    Speaker: Darran O'Connor, PhD
  • OCT 29, 2014 07:30 AM PDT
    Speaker: Vikram Devgan, PhD, MBA
    SEE ABSTRACT | Continuing Education: CE
  • OCT 29, 2014 07:30 AM PDT
    Speaker: Katherine LB Borden, PhD
  • OCT 29, 2014 09:00 AM PDT
    Speaker: Fraser Hof, PhD
  • OCT 29, 2014 09:00 AM PDT
    Speaker: Anna Barker, PhD
  • OCT 29, 2014 09:00 AM PDT
    Speaker: Jonathan Shaffer, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 29, 2014 10:30 AM PDT
    Speaker: Kenneth Buetow, PhD, FACMI
  • OCT 29, 2014 12:00 PM PDT
    Speaker: Kerri Phillips
  • OCT 29, 2014 12:00 PM PDT
    Speaker: Michael MacCoss, PhD
  • OCT 29, 2014 12:00 PM PDT
    Speaker: Liza Makowski, PhD
  • OCT 29, 2014 01:30 PM PDT
    Speaker: Adrienne C. Scheck, PhD
  • OCT 29, 2014 01:30 PM PDT
    Speaker: Walter Ausserer, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 29, 2014 01:30 PM PDT
    Speaker: Mei Kong, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 29, 2014 03:00 PM PDT
    Drug-tailored, efficacy-predictive and prognostic biomarker approaches for proper patient selection
    Speaker: Peter Blume-Jensen, MD, PhD
  • OCT 29, 2014 03:00 PM PDT
    Speaker: Michael J Mann, MD
  • OCT 29, 2014 03:00 PM PDT
    Speaker: Jennifer Stone, PhD
  • OCT 30, 2014 06:00 AM PDT
    Speaker: Naomi Thomson
    SEE ABSTRACT | Continuing Education: CE
  • OCT 30, 2014 06:00 AM PDT
    Speaker: Kristin Landis-Piwowar, PhD, MLS
  • OCT 30, 2014 07:30 AM PDT
    Speaker: Nicola Normanno, MD
  • OCT 30, 2014 09:00 AM PDT
    Speaker: Paul W. Dempsey, PhD
  • OCT 30, 2014 10:30 AM PDT
    Speaker: Kimberly Kelly , PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 30, 2014 10:30 AM PDT
    Speaker: John Carpten, PhD
  • OCT 30, 2014 10:30 AM PDT
    Speaker: William Clarke, PhD, MBA, DABCC
  • OCT 30, 2014 12:00 PM PDT
    Speaker: William M. Gallagher, BSc PhD CBiol MSB
  • OCT 30, 2014 12:00 PM PDT
    Speaker: Julian J. Lum, PhD
  • OCT 30, 2014 12:00 PM PDT
    Speaker: Sharon M. Geaghan, MD
  • OCT 30, 2014 01:30 PM PDT
    Speaker: Nadya Tarasova, PhD
  • OCT 30, 2014 01:30 PM PDT
    Speaker: Ruth Nussinov, PhD
  • OCT 30, 2014 03:00 PM PDT
    Speaker: Josip Blonder, MD
  • OCT 30, 2014 03:00 PM PDT
    Speaker: Christian Metallo, PhD
  • Molecular Profiling and Biomarkers
  • OCT 29, 2014 06:00 AM PDT
    Speaker: Kelli Bramlett, M.S.
  • OCT 29, 2014 07:30 AM PDT
    Speaker: Vikram Devgan, PhD, MBA
    SEE ABSTRACT | Continuing Education: CE
  • OCT 29, 2014 09:00 AM PDT
    Speaker: Anna Barker, PhD
  • OCT 29, 2014 12:00 PM PDT
    Speaker: Michael MacCoss, PhD
  • OCT 29, 2014 01:30 PM PDT
    Speaker: Walter Ausserer, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 29, 2014 03:00 PM PDT
    Drug-tailored, efficacy-predictive and prognostic biomarker approaches for proper patient selection
    Speaker: Peter Blume-Jensen, MD, PhD
  • OCT 29, 2014 03:00 PM PDT
    Speaker: Michael J Mann, MD
  • OCT 30, 2014 06:00 AM PDT
    Speaker: Naomi Thomson
    SEE ABSTRACT | Continuing Education: CE
  • OCT 30, 2014 10:30 AM PDT
    Speaker: Kimberly Kelly , PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 30, 2014 01:30 PM PDT
    Speaker: Ruth Nussinov, PhD
  • Drug Discovery
  • OCT 29, 2014 06:00 AM PDT
    Speaker: Srinivas (Sri) Sridhar, PhD
  • OCT 29, 2014 07:30 AM PDT
    Speaker: Katherine LB Borden, PhD
  • OCT 29, 2014 09:00 AM PDT
    Speaker: Jonathan Shaffer, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 30, 2014 10:30 AM PDT
    Speaker: John Carpten, PhD
  • OCT 30, 2014 03:00 PM PDT
    Speaker: Josip Blonder, MD
  • Clinical Proteomics
  • OCT 29, 2014 07:30 AM PDT
    Speaker: Darran O'Connor, PhD
  • Cancer Epigenetics
  • OCT 29, 2014 09:00 AM PDT
    Speaker: Fraser Hof, PhD
  • OCT 30, 2014 06:00 AM PDT
    Speaker: Kristin Landis-Piwowar, PhD, MLS
  • Keynote
  • OCT 29, 2014 10:30 AM PDT
    Speaker: Kenneth Buetow, PhD, FACMI
  • OCT 30, 2014 07:30 AM PDT
    Speaker: Nicola Normanno, MD
  • OCT 30, 2014 09:00 AM PDT
    Speaker: Paul W. Dempsey, PhD
  • Therapeutics; Cancer Therapies & New Techniques
  • OCT 29, 2014 12:00 PM PDT
    Speaker: Kerri Phillips
  • OCT 29, 2014 01:30 PM PDT
    Speaker: Adrienne C. Scheck, PhD
  • OCT 29, 2014 03:00 PM PDT
    Speaker: Jennifer Stone, PhD
  • OCT 30, 2014 10:30 AM PDT
    Speaker: William Clarke, PhD, MBA, DABCC
  • OCT 30, 2014 12:00 PM PDT
    Speaker: William M. Gallagher, BSc PhD CBiol MSB
  • OCT 30, 2014 12:00 PM PDT
    Speaker: Sharon M. Geaghan, MD
  • Cancer Metabolism
  • OCT 29, 2014 12:00 PM PDT
    Speaker: Liza Makowski, PhD
  • OCT 29, 2014 01:30 PM PDT
    Speaker: Mei Kong, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 30, 2014 12:00 PM PDT
    Speaker: Julian J. Lum, PhD
  • OCT 30, 2014 03:00 PM PDT
    Speaker: Christian Metallo, PhD
  • Cell Signaling
  • OCT 30, 2014 01:30 PM PDT
    Speaker: Nadya Tarasova, PhD
Speakers

  • Kenneth Buetow, PhD, FACMI
    Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University
    Biography
      Dr. Ken Buetow is a human genetics and genomics researcher who leverages computational tools to understand complex traits such as cancer, liver disease, and obesity. Dr. Buetow currently serves as Director of Computational Sciences and Informatics program for Complex Adaptive Systems at Arizona State University (CAS@ASU) and is a professor in the School of Life Sciences in ASU's College of Liberal Arts and Sciences. CAS@ASU applies systems approaches that leverage ASU's interdisciplinary research strengths to address complex global challenges. The Computational Sciences and Informatics program is developing and applying information technology to collect, connect, and enhance trans-disciplinary knowledge both within ASU and across the broader knowledge-generating ecosystems. CAS@ASU is creating a Next Generation Cyber Capability to address the challenges and opportunities afforded by "Big Data" and the emergence of 4th Paradigm Data Science. This capability brings state-of-the-art computational approaches to CAS@ASU's transdisciplinary, use-inspired research efforts Dr. Buetow previously served as the Director of the Center for Biomedical Informatics and Information Technology within the National Institutes of Health's National Cancer Institute (NCI). In that capacity he initiated and oversaw the NCI's efforts to connect the global cancer community through community-developed, standards-based, interoperable informatics capabilities that enable secure exchange and use of biomedical data. Buetow designed and built one of the largest biomedical computing efforts in the world. He was responsible for coordinating biomedical informatics and information technology at the NCI. The NCI center he led focused on speeding scientific discovery and facilitated translational research by coordinating, developing and deploying biomedical informatics systems, infrastructure, tools and data in support of NCI research initiatives.
    • Darran O'Connor, PhD
      Senior Lecturer, School of Biomolecular & Biomedical Science, Co-Director, Cancer Biology & Therapeutics Laboratory, University of Dublin
      Biography
        I obtained my PhD from Trinity College Dublin in 2000. Subsequently, I conducted my postdoctoral training in cancer biology at Columbia University, New York and at the University of Glasgow under the supervision of Prof Nick La Thangue, FRSE. Afterwards, I returned to Ireland as a HRB Career Development Fellow and, in 2009, was employed in a permanent capacity as a Research Fellow in Cancer Biology at UCD within the School of Biomolecular and Biomedical Science and appointed as Senior Lecturer in Cancer Biology within SBBS in 2013. At present, I lead a team of 3 postdoctoral fellows and 3 PhD students (with 4 previous PhD students graduated) funded by the European Commission, Science Foundation Ireland, The Irish Cancer Society and the Irish Research Council for Science, Engineering and Technology. My group has extensive experience in the discovery of molecular determinants of cancer progression (via transcriptomic/proteomic profiling and functional genomic screening) and their clinical translation through the development and automated analysis of tissue microarrays, in addition to their functional analysis using in vitro models and xenograft studies in nude mice. As such, we have established an integrated workflow for the molecular and clinical analysis of central tumourigenic processes that we are currently applying to a number of different tumour types. Based on this work I was elected to the council of the Irish Association for Cancer Research in 2011 and was awarded the 9th St Luke's Young Investigator award in 2012 and an EACR Young Scientist Award in 2009. Additionally, I have been awarded a number of prestigious fellowships, notably from the Health Research Board, the European Molecular Biology Organisation and the Human Frontiers Science Programme and have spent additional time as a Visiting Fellow at the Dana-Farber Cancer Institute/Harvard Medical School and the Netherlands Cancer Institute where I joined the group of Prof Rene Bernards. I have published 33 articles to date in Nature Cell Biology, Nature Reviews Cancer, Oncogene, EMBO Reports, Cancer Research and Clinical Cancer Research among others.
      • Nicola Normanno, MD
        Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy
        Biography
          Dr. Normanno earned his Medical Doctor Degree in 1988 at the Medical School of the University of Naples (Italy) Federico II. He received his spacialization in Medical Oncology in 1991, and in Hematology in 2001, at the same university. Between 1990 and 1993, Dr. Normanno completed a postoctoral fellowship studying tumor growth factors at the National Institutes of Health, Bethesda, MD. Since 1993, Dr. Normanno's areas of research have been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; and identification of markers of response or resistance to anti EGFR agents. Dr. Normanno is a member of the American Association for Cancer Research, the Italian Tumor Society, and the Italian Cancer Society. He is the author of over 140 papers published in peer reviewed journals. After serving as Senior Investigator, and later, Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy Unit at the same Hospital, and since 2006, is also Director of the Research Department.
        • Paul W. Dempsey, PhD
          Chief Science Officer, Cynvenio
          Biography
            Dr. Dempsey is an immunologist by training with more than 25 years of experience in biomedical research. Before joining Cynvenio, Dr. Dempsey was an Assistant Research Professor in the Department of Microbiology, Immunology and Molecular Genetics at the University of California, Los Angeles. He brings extensive hands-on research experience in life sciences, molecular biology, and reagent development. <br /> <br />Dr. Dempsey was a Leukemia and Lymphoma Society Fellow from 2000 to 2003, has published 20 scientific articles and abstracts, and holds patents in technologies designed to amplify the immunogenicity of vaccines and rare-cell recovery. <br /> <br />Dr. Dempsey holds a BS in Microbiology and Virology from the University of Warwick in Coventry, UK, and a PhD from Johns Hopkins University School of Medicine. <br />
          • John Carpten, PhD
            Deputy Director of Basic Science, Professor and Director Integrated Cancer Genomics Division, TGen
            Biography
              Dr. Carpten received his Ph.D. from the Department of Molecular Genetics, The Ohio State University in 1994. Prior to joining TGen, Dr. Carpten was an intramural tenure track investigator with the Cancer Genetics Branch of the National Human Genome Research Institute (NHGRI), NIH, a group that pioneered a number of innovative technologies and methods to study the underlying genetics of cancer. Dr. Carpten, has made a number of seminal discoveries in cancer genetics and genomics.  While a fellow and later a tenure track investigator at NHGRI/NIH, he co-led the first published genome wide scan for prostate cancer susceptibility genes published in 1996 in Science. His lab subsequently discovered germ-line mutations in the RNASEL gene in HPC1-linked hereditary prostate cancer families. His contigs of the 1q24-q31 region of the human genome became the framework and template for sequencing of that 20 megabase region by the Human Genome Project. Also mutations in the HRPT2 gene, which maps to 1q31, were discovered in the Carpten lab and lead to hyperparathyroidism jaw-tumor syndrome. Dr. Carpten also has an intense focus on understanding the role of biology in disparate cancer incidence and mortality rates seem among minority populations. Through his leadership, the African American Hereditary Prostate Cancer Study (AAHPC) Network was conceived.  This study has become a model for genetic linkage studies in underrepresented populations and led to the first genome wide scan for prostate cancer susceptibility genes in African Americans.  More recently, his group has discovered a number of single nucleotide polymorphisms, which confer increased risk of developing prostate cancer.  He has recently led and co-authored a series articles describing the roles of genetic variants in prostate cancer risk in Genome Research, Journal of the National Cancer Institute, and the New England Journal of Medicine.
            • Josip Blonder, MD
              Group Leader - Clinical Proteomics, Cancer Research Technology Program (CRTP), Frederick National Laboratory for Cancer Research (FNL), Leidos Biomedical Research, Inc.
              Biography
                Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI).  In 1978, Dr. Blonder received his M.D. at the Rijeka University School of Medicine, Croatia. In 2000, through Associated Western Universities, Dr. Blonder was awarded a post-doc fellowship in proteomics at the Pacific Northwest National Laboratory (PNNL), Richland, WA (Advisor: Dr. Richard D. Smith). At the PNNL, his research was focused on studying cell surface proteins using mass spectrometry (MS)-based proteomics. In 2002, Dr. Blonder joined FNL (formerly NCI-Frederick) where he continues to develop and apply MS-based proteomics to cancer research. Since 2006, he has led the Clinical Proteomics Group, extending his research on development of shotgun proteomics for in-depth profiling of membrane proteins found at the cell surface of cancer cells. In parallel, he worked on methodology for cancer biomarker and drug target discovery using precision proteomics for targeted profiling of clinical tissue and blood specimens. His group was the first to optimize the immunodepletion of abundant proteins from clinical tissue homogenates. Currently, Dr. Blonder is leading the effort towards molecular mapping of the KRAS cell surface as a part the RAS program. This program is spearheaded by the FNL as a national mission to attack RAS-driven cancers. Dr. Blonder brings unique combination of his expertise in medicine, clinical proteomics, and pathway analysis, focusing his research on the development of innovative approaches for molecular profiling of cancer cell lines, body fluids and tissue specimens. He is an editor of BMC Cancer and a lecturer at the Foundation for Advanced Education in the Sciences at NIH. Since 2002, Dr. Blonder has authored over 50 scientific publications in areas of biological mass spectrometry, clinical proteomics and cancer research. 
              • Kristin Landis-Piwowar, PhD, MLS
                Assistant Professor, Biomedical Diagnostic &amp; Therapeutic Sciences, , Oakland University
                Biography
                  Kristin Landis-Piwowar is an Assistant Professor of Biomedical Diagnostic and Therapeutic Sciences at Oakland University in Rochester, MI. She earned a bachelors degree from Ferris State University in Medical Technology, a Masters degree in Clinical Laboratory Science from Michigan State University and a PhD in Cancer Biology from Wayne State Universitys School of Medicine in the laboratory of Q. Ping Dou. Landis-Piwowar was awarded a post-doctoral fellowship at the University of Michigan, Department of Pathology, where she conducted research to understand CD30 signaling to NFkB in anaplastic large cell lymphoma. Landis-Piwowar joined the faculty at Oakland University in Rochester, MI where she currently holds rank as an Assistant Professor of Biomedical Diagnostic and Therapeutic Sciences. Landis-Piwowar has published more than 25 peer-reviewed journal articles on cancer therapeutics, prevention, and mechanisms of disease and has authored numerous book chapters. Her research interests are centered on the physiologic effects of gold-peptidomimetics in cancer cells, and deciphering a familial relationship among chronic lymphocytic leukemia and hairy cell leukemia.
                • Julian J. Lum, PhD
                  Scientist BC Cancer Agency's Deeley Research Centre, Assistant Professor Department of Biochemistry and Microbiology, University of Victoria
                  Biography
                    Dr. Julian J. Lum graduated with a PhD in Immunology from the University of Ottawa. He spent five years training at the University of Pennsylvania in the field of cancer biology with special emphasis on tumor metabolism. There he studied how cells adapt to nutrient stress and the role of autophagy in promoting cancer cell survival. In 2008, Dr. Lum returned to Canada and joined the Deeley Research Centre at the BC Cancer Agency, as a Scientist where his current research interest is in autophagy and metabolism of clear cell ovarian adenocarcinoma. He hopes the information gained from this work will enable a better understanding of how the tumor microenvironment influences the immune response to cancer. Dr. Lum is an Assistant Professor with the Department of Biochemistry and Microbiology, University of Victoria. He is also the recipient of a CIHR New Investigator Award. His work is funded by the BC Cancer Foundation, CIHR and Genome BC.  
                  • Christian Metallo, PhD
                    Principal Investigator, Metallo Lab, Assistant Professor, Bioengineering, University of California, San Diego
                    Biography
                      Christian Metallo joined the University of California, San Diego in 2011 and is currently an assistant professor in the Department of Bioengineering. He received his bachelors in chemical engineering from the University of Pennsylvania in 2000 before joining Merck Research Laboratories to conduct bioprocess engineering research.  He received his Ph.D. from the University of Wisconsin-Madison Department of Chemical and Biological Engineering in 2008 and was an American Cancer Society Postdoctoral Fellow in Chemical Engineering at the Massachusetts Institute of Technology.  Christian was the recipient of the Biomedical Engineering Society Rita Schaffer Young Investigator Award in 2012 and is a 2013 Searle Scholar. Dr. Metallo is also the Principal Investigator at the Metallo laboratory which conducts research in the area of systems biology applied to cancer and stem cell metabolism. They utilize stable isotope tracers, mass spectrometry, and computational tools for metabolic flux analysis (MFA) to study the function of metabolism in disease models. Their work aims to characterize the dynamic interplay between metabolism, signal transduction, and cellular fate choices by understanding how intracellular signals and the microenvironment regulate metabolic fluxes. 
                    • Naomi Thomson
                      Director, Clinical Analytics and Workflow Products, CLC Bio, a Qiagen company
                      Biography
                        Naomi is greatly experienced within the field of bioinformatics from where she has gained a tremendous amount of customer, product, and sequencing experience through the past 15 years. Naomis pre-business experience is loaded with nucleic acids and oncology at Bristol-Myers Squibb and The Wistar Institute, along with an MBA from La Salle University. Naomi has also been working 10 years as a Product Manager and nearly five years as an NGS Key Account Manager before heading the product management of Clinical Analytics and Workflow products at QIAGEN.
                      • Kimberly Kelly , PhD
                        Associate Professor of Biomedical Engineering, University of Virginia
                        Biography
                          Dr. Kimberly Kelly is an Associate Professor in the Department of Pharmaceutical Systems and Policy in the School of Pharmacy and the Mary Babb Randolph Cancer Center. She received her MS (1998) and PhD (2000) in social and health psychology from Rutgers University, her MS (2002) in genetic counseling from Indiana University, and completed a post-doctoral fellowship in cancer control and behavioral science at the University of Kentucky (2002-2004). Before joining West Virginia University, Dr. Kelly was a member of the Department of Molecular Virology, Immunology, and Medical Genetics, and was also affiliated with the Department of Psychology, Health Behavior and Health Promotion in the College of Public Health, the Primary Care Research Institute, and the Comprehensive Cancer Center at The Ohio State University. Three overlapping themes emerge from Dr. Kellys research: (1) cancer risk perception/communication, (2) health behavior (e.g., cancer screening, genetic testing), and (3) elevated risk populations (e.g., Appalachians, those with a family history of cancer). Her work relies on behavioral theory from psychology (health, social, cognitive), as well as communication and information sciences. She mixes qualitative and quantitative methods, utilizing clinic-based and community-based approaches. Most of her research has focused on how risk is communicated in the context of cancer genetic counseling and how risk perceptions differ from objective estimates of risk. She also examines the role of risk perception in cancer screening. Through her research, Dr. Kelly hopes to understand how best to enhance appropriate decision-making about health behaviors in elevated risk populations to accomplish optimal health outcomes. 
                        • Ruth Nussinov, PhD
                          Head, Computational Structural Biology Group, Senior Investigator, Center for Cancer Research, National Cancer Institute
                          Biography
                            Dr. Ruth Nussinov is a Professor in the Department of Human Genetics, School of Medicine, Tel Aviv University, Tel Aviv, 69978 Israel, and a Senior Principal Scientist and Principal Investigator at the National Cancer Institute. She has received her B. Sc degree in Microbiology from the University of Washington (Seattle, Washington) and her Ph.D. in Biochemistry from Rutgers University (NJ). She was a Fellow at the Weizmann Institute, and a visiting scientist at the chemistry department at Berkeley and at the Biochemistry department at Harvard. She joined the Medical School at Tel Aviv University in 1985 as an Associate Professor. In 1990 she became a Full Professor. Her association with the NIH started in 1983, first with the NICHHD and since 1985 with the NCI. Currently, she has a large group of graduate students in Tel Aviv, in collaboration with Prof. H. Wolfson, from the School of Computer Science. Additionally, she has a group at the NCI. She is an author of over 470 scientific papers. Dr. Nussinov's 1978 paper proposed the dynamic programming algorithm for RNA secondary structure prediction (e.g. in wikipedia/encyclopedia/course lectures, etc.)
                          • William Clarke, PhD, MBA, DABCC
                            Associate Professor of Pathology, Clinical Toxicology, Director, Point-of-Care Testing, Johns Hopkins University School of Medicine
                            Biography
                              Dr. William Clarke is an associate professor of pathology at the Johns Hopkins University School of Medicine. His research focuses on the development of analytical methods for drug analysis, clinical mass spectrometry, and devices for point-of-care testing. Dr. Clarke serves as the director of Clinical Toxicology as well as Critical and Point-of-Care Testing Program at The Johns Hopkins Hospital. His team's current projects include qualitative screening for antiretroviral drugs and substances of abuse in various HIV- prevention clinical trials, development and validation of mass spectrometry methods for clinical analysis, and development of clinical assays for use on microfluidic platforms. Dr. Clarke received his B.S. in Chemistry from the University of Nebraska at Kearney and his Ph.D. in Analytical Chemistry from the University of Nebraska-Lincoln, as well as an M.B.A. from the Carey School of Business at Johns Hopkins University. He completed a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine.
                            • Sharon M. Geaghan, MD
                              Chief, Pathology at Lucile Packard Children's Hospital at Stanford, Associate Professor in the Department of Pathology, Stanford University
                              Biography
                                Dr. Geaghan is Chief, Pathology at Lucile Packard Children's Hospital at Stanford, and Co-Director of Clinical Laboratories at Stanford Hospital and Clinics. She also directs the Bass Pediatric Cancer Center Laboratory at the Lucile Packard Hospital; is Director of the Point of Care Testing Program for the women and children's hospital and is Director of Stanford Clinical Laboratory at Mary L. Johnson Pediatric Ambulatory Care CenterShe is an Associate Professor in the Department of Pathology and in Pediatrics at Stanford University School of Medicine, teaching medical students, residents, fellows and post-graduate continuing medical education programs. Dr. Geaghan received her undergraduate degree at Dartmouth College and MD at Boston University School of Medicine. She received her training, including two residencies in Anatomic and Surgical Pathology and in Laboratory Medicine, at the University of California, San Francisco, where she also served as Chief Resident and was the first Hematopathology Fellow. Dr. Geaghan holds four board certifications: in Anatomic Pathology; Hematopathology; Clinical Pathology and Pediatric Pathology. Dr. Geaghan is Chair-elect of the American Association of Clinical Chemistry Division of Pediatric Maternal Fetal Division, the largest organization of laboratory medicine professionals (2012-2014). Dr. Geaghan was recently named to the International Federation of Clinical Chemistry's Task Force on Pediatric Laboratory Medicine, and the College of American Pathologists Point of Care Testing Committee. Dr. Geaghan serves on numerous Executive Boards, including the Medical Executive Board at Lucile Salter Packard Children's Hospital at Stanford and also serves on Advisory Boards as an avid advocate for children's health, in various national Pediatric Clinical and Laboratory Medicine Associations. She has recently been named in Top Doctors of the Year by San Jose Magazine, and in the American Registry of Outstanding Professionals.  
                              • William M. Gallagher, BSc PhD CBiol MSB
                                Chief Scientific Officer at OncoMark, Professor of Cancer Biology, University of Dublin
                                Biography
                                  Prof. Gallagher originally graduated from the Department of Biochemistry, UCD in 1993 with a 1st Class Joint Honors degree in Molecular Genetics and Biochemistry. Subsequently, he obtained a PhD in Molecular Oncology from the Cancer Research UK Beatson Laboratories in Glasgow. In 1997, he moved to Paris to undertake a Marie Curie Individual Fellowship at Rhone-Poulenc Rorer (currently Sanofi-Aventis). Afterwards, he returned to Ireland upon receipt of an Enterprise Ireland Post-Doctoral Fellowship (1999-2000) and, subsequently, a Marie Curie Return Fellowship (20002001). In 2001, he was employed in a permanent capacity as College Lecturer at UCD within the former Department of Pharmacology. In 2005, he was appointed Senior Lecturer within the UCD School of Biomolecular and Biomedical Science, promoted to Associate Professor of Cancer Biology in 2006 and Full Professor in 2014. From September 2009-August 2011, Prof. Gallagher was the Vice-Principal of Research and Innovation at the UCD College of Life Sciences. He is also a Conway Fellow at the UCD Conway Institute. In 2007, he co-founded OncoMark Ltd., which is a private company centred on the development and application of biomarker panels and associated technologies, on both tissues and biological fluids (www.oncomark.com). Prof. Gallagher is currently the Chief Scientific Officer (CSO) at OncoMark. A major focus of his research work is the identification and validation of candidate biomarkers of breast cancer and melanoma, with particular emphasis on translation of transcriptomic and proteomic datasets into clinically relevant assays.    Prof. Gallagher has received a number of awards based on his research work to date, including the BACR/AstraZeneca Young Scientist Frank Rose Award in 2004, the St. Lukes Silver Medal Award in 2008 and the NovaUCD 2011 Innovation Award. Prof. Gallagher has had productive collaborative interactions with a variety of other industrial partners throughout his research.   
                                • Jennifer Stone, PhD
                                  Senior Market Manager, Oncology , Illumina
                                  Biography
                                    Dr. Jennifer Stone joined Illumina in 2009 and is responsible for market development for the oncology business.  Before joining Illumina, Dr. Stone held a post-doctoral fellowship position at the Broad Institute of Harvard and MIT and Massachusetts General Hospital, with a focus on complex disease genetics and large-scale study design and analysis.  She earned a bachelors in chemistry from The College of William and Mary in Virginia, and an PhD in Human Genetics from the University of California, Los Angeles..
                                  • Adrienne C. Scheck, PhD
                                    Associate Professor, Neuro-Oncology Research, Barrow Brain Tumor Research Center, Barrow Neurological Institute
                                    Biography
                                      Adrienne C. Scheck, PhD, is an Associate Professor at the Barrow Neurological Institute in Phoenix, Arizona. She is also an Adjunct Professor in the School of Life Sciences at Arizona State University and an Associate Investigator in the Cancer Biology Program at the Arizona Cancer Center of the University of Arizona. Dr. Scheck received her undergraduate degree from the University of Rochester in NY and her PhD from Rensselaer Polytechnic Institute in Troy, NY. After a postdoctoral fellowship in viral oncology at the Pennsylvania State College of Medicine in Hershey, Pennsylvania she moved to Memorial Sloan-Kettering Cancer Center to study AIDS-related dementia. She began her studies of brain tumors while at Sloan-Kettering and moved to the Barrow Neurological Institute in 1989. Current work in her laboratory has 2 major goals. The first is to devise novel therapeutic regimens to improve survival and minimize side effects for patients with malignant brain tumors. To this end, her laboratory has been studying the use of the ketogenic diet (KD) for the treatment of malignant brain tumors. Their work has shown that the KD reduces the growth of malignant brain tumors through a variety of mechanisms, and it potentiates the effect of radiation and temozolomide chemotherapy (the standard of care for patients with grade IV brain tumors). These preclinical studies have led to a clinical trial for patients with glioblastoma multiforme (www.clinicaltrials.gov NCT02046187). The second main goal of her research is to identify markers that improve on the current methods of diagnosis and prognosis for this devastating disease. In addition to her love for horses, one of Adriennes pet projects comes from her interest in science education. She directs a program that places high school students in research laboratories and gives Cancer Biology lectures to area high school students, and she was a co-principal investigator on a Science Education grant with the Arizona Science Center.
                                    • Srinivas (Sri) Sridhar, PhD
                                      Director, NSF IGERT Nanomedicine Science and Technology Program, Director, Electronic Materials Research Institute, Arts and Sciences Distinguished Professor of Physics, Lecturer on Radiation
                                      Biography
                                        Srinivas Sridhar is Arts and Sciences Distinguished Professor of Physics at Northeastern University, and Visiting Professor of Radiation Oncology, Harvard Medical School. He is the Director and Principal Investigator of Nanomedicine Science and Technology, an IGERT (Integrative Graduate Education and Research Training) program funded by the National Cancer Institute and the National Science Foundation. He is the founding director of the Electronic Materials Research Institute, an interdisciplinary center with research and education thrusts in nanophotonics and nanomedicine. From 2004 to 2008 he served as Vice Provost for Research at Northeastern University, overseeing the Universitys research portfolio. An elected Fellow of the American Physical Society, Sridhars current areas of research are nanomedicine and nanophotonics. He has published more than 160 articles on his work in nanomedicine, nanophotonics, metamaterials, quantum chaos, superconductivity and collective excitations in materials.
                                      • Katherine LB Borden, PhD
                                        Principal Investigator, Structure and Function of the Cell Nucleus research unit, Full Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Instit
                                        Biography
                                          Dr Borden is a full professor at the Institute for Research in Immunology and Cancer at University of Montreal. She obtained her PhD with Fred Richards at Yale University in Molecular Biophysics and Biochemistry and trained in NMR and cell biology in London with Andrew Lane at the National Institute for Medical Research and with Paul Freemont at the Imperial Cancer Research Fund (now Cancer Research UK). She has a long standing interest in combining structural, biophysical and cell biological methods to better understand how dysregulated mRNA metabolism can contribute oncogenesis. Currently, she studies the eukaryotic translation initiation factor eIF4E with particular emphasis on its mRNA export functions. Her biophysical and cell biological studies have identified an inhibitor of eIF4E, ribavirin. Ribavirin has been shown to target eIF4E activity in leukemia patients where this correlates with clinical responses including remissions.
                                        • Jonathan Shaffer, PhD
                                          Senior Scientist, Product Development, Qiagen
                                          Biography
                                            Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being miRNA technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. Currently, Dr. Shaffer is a Senior Scientist in product development at QIAGEN .
                                          • Fraser Hof, PhD
                                            Associate Professor, University of Victoria
                                            Biography
                                              Fraser was born in 1976, raised in Medicine Hat, Alberta, and got his start in chemistry with a B.Sc. at the University of Alberta. In 1998 he moved to warmer climes at the Scripps Research Institute in La Jolla, California to study supramolecular chemistry with Julius Rebek, Jr. After obtaining his Ph.D. at Scripps, he was a Novartis Foundation (2003) and Human Frontier Science Program (2004) post-doctoral fellow studying medicinal chemistry in the labs of Franois Diederich at the Swiss Federal Institute of Technology (ETH-Zurich). Finally returning home to western Canada, he took up his position at the University of Victoria in 2005. Frasers research program creates new chemical tools for studying and disrupting epigenetic stem cell regulation, with the goals of understanding the basic mechanism of epigenetic programming of stem cells, and of creating new treatments for the most aggressive, stem-like cancers of prostate, breast, and blood.
                                            • Liza Makowski, PhD
                                              Assistant Professor, Nutrition, UNC Gillings School of Global Public Health
                                              Biography
                                                Liza Makowski is an assistant professor of Nutrition, Division of Nutrition Biochemistry in the Departments of Nutrition and Medicine at the UNC Gillings School of Global Public Health and the UNC School of Medicine. She earned a Ph.D. in the Department of Nutrition at the Harvard School of Public Health and a Masters in Medicine concurrent with her Ph.D. studies as a Lucille P. Markey Fellow from Harvard Medical School. Liza completed postdoctoral studies in the Departments of Medicine and Pharmacology & Cancer Biology at the Duke University Stedman Center for Nutrition and Metabolism. Dr. Makowski has expertise in metabolism, inflammation, mouse models, macrophage biology, and nutrient sensitive signaling pathways. The research focus of the Makowski Lab (http://makowskilab.web.unc.edu/) is to understand metabolic reprogramming of immune cells wherein the goal is to identify novel pathways to manipulate substrate metabolism in immune cells in efforts to limit the pathogenesis of complex diseases such as obesity and diabetes. Dr. Makowski has received multiple grants including a Pathway to Independence NIH K99/R00 award to investigate macrophage mitochondrias role in metabolism and inflammation. She is currently PI on an NIH R21 Provocative Question Grant and a Mary Kay Foundation grant to study obesity and breast cancer risk, and an American Heart Association grant to study substrate metabolism in macrophage biology. Her ultimate aim is to find relevant metabolically sensitive pathways in her model systems, observe parallels in human populations, and identify targets to reprogram immune cells that will restore tissue homeostasis thereby reducing progression of obesity, diabetes, atherosclerosis, and cancer.
                                              • Mei Kong, PhD
                                                Assistant Professor, Cancer Biology , City of Hope National Medical Center
                                                Biography
                                                  Mei Kong, Ph.D.  is an assistant professor in the Department of Cancer Biology at Beckman Research Institute of City of Hope Cancer Center. She  received her Ph.D. at McGill Univeristy in Canada in Cell Biology.  She then studied cell signaling and cancer metabolism at University of Pennsylvania as an American Association for Cancer Research postdoctoral fellow and then later as a Leukemia Lymphoma Society special fellow.  Dr. Kong is a recepient of the Innovative Research Grant from Stand up to Cancer. She is also a Pew Scholar, Sidney Kimmel Scholar, and V Scholar in Cancer Research.  Dr. Kong studies the oncogenic signal transduction pathways, focusing on the metabolic stress response in tumor cells.
                                                • Kelli Bramlett, M.S.
                                                  Research &amp; Development Scientist, Thermo Fisher Scientific
                                                  Biography
                                                       Dr. Bramlett leads the RNA Sequencing Applications Team at Life Sciences Solutions, Thermo Fisher Scientific. She guides the Research & Development effort focused on creating innovative sequencing and data analysis solutions for the detailed analysis of RNA. Prior to joining Thermo Fisher Scientific, Dr. Bramlett was a drug development scientist at Eli Lilly and Company, where she led a team of scientists specializing in gene regulation and nuclear receptor biology to identify novel drug targets. Dr. Bramlett built her background and experience in gene regulation through prior academic positions at Baylor College of Medicine and the M.D. Anderson Cancer Center. Kelli holds an undergraduate degree in Chemistry from Rice University in Houston, Texas, and a masters degree in Pharmacology from the Indiana University School of Medicine in Indianapolis, Indiana.
                                                  • Vikram Devgan, PhD, MBA
                                                    Director, Head of Biological research content, Qiagen, Inc.
                                                    Biography
                                                      Dr. Devgan is the head of the Biological Research Content, QIAGEN. He received his Ph.D. in molecular biology and conducted post-doctoral research at Harvard Medical School before moving to the biotechnology industry. He received his MBA from the University of Wurzburg in Germany and has spent many years as a scientist in developing new technologies and products clinical and translational research.
                                                    • Anna Barker, PhD
                                                      Co-Director, Complex Adaptive Systems Initiative, Director, Transformative Healthcare Networks, Professor, School of Life Sciences, Arizona State University (ASU)
                                                      Biography
                                                        Co-Director of Complex Adaptive Systems at ASU, Dr. Barker designs and implements transformative networks to enable the convergence of knowledge, innovative teams and novel funding approaches to address major problems in biomedicine. Several initiatives are underway, including: the National Biomarker Development Alliance NBDA; a program to re-think diseases that are particularly difficult to diagnose and treat; and a consortium focused on deep phenotyping in silico medicine. Prior to joining ASU, Dr. Barker served for several years as Deputy Director of the National Cancer Institute (NCI) and Deputy Director for Strategic Scientific Initiatives. At the NCI she developed and led or co-led a number of transdisciplinary programs including the: The Cancer Genome Atlas (TCGA); Nanotechnology Alliance for Cancer; Clinical Proteomics Technologies Initiative for Cancer; and the Physical Sciences- Oncology Centers (PS-OCs). She co-chaired the NCI-FDA Interagency Task Force (IOTF) and was founding co-chair of the Cancer Steering Committee of the FNIH Biomarkers Consortium (FNIH-BC). Achievements from these groups included the exploratory IND (IOTF); and oversight of the design and implementation of the ISPY-2 Trial (FNIH-BC). She served as a research scientist and a senior executive at Battelle Memorial Institute for 18 years; and subsequently co-founded and served as the CEO of a public biotechnology company. Examples of her public service include: the National Coalition of Cancer Research; Partner and Member of the Board of Directors of C-Change; Chairperson, C-Change Cancer Research Team; Founding member, Department of Defense (DOD) Breast Cancer Research Program (BCRP) and Chairperson of the Integration Panel (IP); a number of roles for the American Association for Cancer Research (AACR), including the Board of Directors and chairperson, Science Policy and Legislative Affairs Committee; member of NCIs Board of Scientific Counselors, Division of Cancer Etiology; and Chairperson, NCI Cancer Center Support Review Study Section. Dr. Barker has received a number of awards for her efforts in science and advocacy for cancer research. Her research interests include complex adaptive systems science, biomarkers, experimental therapeutics and free-radical biochemistry in cancer etiology and treatment. Dr. Barker completed her M.A. and Ph.D. at The Ohio State University, where she trained in immunology and microbiology.
                                                      • Michael MacCoss, PhD
                                                        Professor of Genome Sciences, University of Washington, School of Medicine
                                                        Biography
                                                          Michael MacCoss has been working with mass spectrometry instrumentation since 1994 when he was an undergraduate in a stable isotope geochemistry lab at the University of Vermont.  He became interested in biomedical applications working in Dr. Patrick Griffins protein mass spectrometry lab at Merck Research Laboratories during two summer internships in 1995 and 1996.  In 2001, he completed a Ph.D. in Analytical Chemistry with Professor Dwight Matthews in the development of stable isotope and mass spectrometry methodologies for the measurement of human amino acid and protein metabolism.  After completing his degree, Dr. MacCoss moved to The Scripps Research Institute to work with Professor John R. Yates III as a postdoctoral fellow.  During his postdoctoral training, Dr. MacCoss worked on methodology and software for many areas of proteomics, ranging from the improved characterization of post-translational modifications and the quantitative analysis of complex protein mixtures.  Dr. MacCoss moved to the University of Washington in 2004 as an Assistant Professor of Genome Sciences, where his lab has focused on the development and application of mass spectrometry based technologies for the high throughput characterization of complex protein mixtures.  In 2009 he was promoted to Associate Professor and in 2014 he was promoted to full professor.
                                                        • Walter Ausserer, PhD
                                                          Business Unit Management, Senior Business Unit Manager, The Jackson Laboratory
                                                          Biography
                                                            Dr. Walter Ausserer leads the In Vivo Pharmacology Services business unit at The Jackson Laboratory, which specializes in mouse models engrafted with human tissues. Over the past two decades, he has held senior positions at leading bioanalytical technology companies, including ProteinSimple, ForteBio, and Caliper Life Sciences. Dr. Ausserer holds a Ph.D. in Chemistry from Cornell University and received postdoctoral training in Cancer Biology in the laboratory of Robert Sutherland at SRI International.
                                                          • Peter Blume-Jensen, MD, PhD
                                                            Chief Scientific Officer, XTuit Pharmaceuticals, Inc.
                                                            Biography
                                                              Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, and targeted oncology therapeutics drug discovery prior to joining Metamark as CSO in 2010.&nbsp; From 2001 to 2008 Peter was department head at first Serono, US and later at Merck Research Laboratories, Merck &amp; Co, Inc. where he established novel, integrated oncology drug discovery departments and programs linking therapeutics to patient responder populations. During his tenure he advanced a number of pre-clinical drug programs into the clinic, and provided translational support for clinical programs. Since 2008 he was Exec. Dir. and Vice President for External Scientific Affairs at Daiichi Sankyo Inc., served as the global 'Therapeutic Area Advisor' for Oncology, and was co-responsible for formulating a global oncology R&amp;D strategy. He co-led the scientific M&amp;A and due diligence resulting in the acquisition of Plexxikon (US$935M).&nbsp; In 2010 he joined Metamark as CSO and 2nd employee.&nbsp; Here he built and let R&amp;D, a world-class KOL Advisory Board, and a novel, automated proteomics imaging platform for CLIA-certified cancer tests.&nbsp; He designed and let 4 clinical studies culminating with the successful blinded, clinical validation of ProMark, a prognostic prostate cancer biopsy test for intact tissue.&nbsp; During the initial commercial launch in Q1-2, 2014 he led Medical Affairs and training of all commercial staff.&nbsp; Since June 2014, Peter has joined Xtuit Pharmaceuticals, a targeted therapeutics start-up, as CSO, and first employee.&nbsp; Peter continues to serve as Chief Scientific Advisor and on the SAB for Metamark and also has joined the SAB of Veritas Gene, Inc, a NGS company. <br /> <br />Dr. Blume-Jensen has authored highly-cited original articles, reviews, and book chapters in Personalized Molecular Oncology. His review 'Oncogenic Kinase Signaling' in Nature is a citation classic in 'Clinical Medicine', and his work on genetically engineered cancer and male infertility mouse models has been widely portrayed on CNN and other news channels. His approaches for efficacy-predictive biomarkers have appeared on Nature Biotechnology's 'Hot patents' watch-list and in numerous Editorial highlights for Personalized Oncology. Dr. Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin's laboratory at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral studies in Dr. Tony Hunter's laboratory at the Salk Institute, La Jolla, CA. He has consulted extensively for Biotech and Pharma on targeted therapeutics and Precision Medicine. <br />
                                                            • Michael J Mann, MD
                                                              Associate Professor of Surgery, Division of Adult Cardiothoracic Surgery, Chief of General Thoracic Surgery, University of California, San Francisco, VA Medical Center
                                                              Biography
                                                                Michael J. Mann, M.D. is a leader in the development of genetic and molecular therapies and diagnostics for thoracic and cardiovascular disease. Dr. Mann joined the UCSF Thoracic Oncology Program in 2003 as a cardiothoracic surgeon. He had received an A.B. in synthetic chemistry from Princeton University and an M.D. from Stanford University, and was awarded a Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship through the NIH. Dr. Mann completed his General Surgery residency at Brigham and Women's Hospital/Harvard Medical School, where he also served on the Faculty of Cardiovascular Medicine, and completed his Cardiothoracic Surgery fellowship at UCSF. Dr. Mann is widely admired for his teaching skills and is Associate Director of the Thoracic Surgery Training Program at UCSF. He holds memberships in numerous professional organizations, including the Society of Thoracic Surgeons, American College of Surgeons, American Heart Association, and the Massachusetts Medical Society. Highly respected by his peers, Dr. Mann was named to the list of U.S. News "Top Doctors;" his areas of clinical expertise include lung cancer, management of metastatic disease in the chest, sarcoma, mesothelioma, and minimally invasive (video-assisted) thoracoscopic surgery. He has received numerous awards including the Cardiovascular Medicine Award for Excellence in Research and the William Randolph Hearst Endowment for Young Investigators. Dr. Mann also serves as a scientific reviewer for numerous professional journals.   While on the faculty at Harvard Medical School, Dr. Mann founded the Cardiovascular Gene Therapy Group. He also invented several novel drug and delivery technologies and helped pioneer the application of gene regulation and vascular biology principles to the problem of coronary bypass graft failure. This led to one of the first large scale programs to evaluate the surgical integration of an advanced molecular therapy. More recently, Dr. Mann's focus on oncogenic signaling pathways and molecular profiles of lung cancer and sarcoma has led to the development and international validation of a molecular diagnostic assay that has enabled personalization of the management of early stage lung cancer. Dr. Mann's research in genetic and molecular therapies has been widely recognized, and he is a founder of the first international co-operative study group designed to harness immense untapped clinical research resources in mainland China. He is currently an Associate Investigator in the UCSF Cardiovascular Research Institute, has served as a scientific advisor to the American Heart Association, to the NIH Recombinant-DNA Advisory Committee and to numerous device and pharmaceutical companies, and his Cardiothoracic Translational Research Laboratory has enjoyed continuous NIH R01 funding since its founding in 2006.
                                                              • Kerri Phillips
                                                                Clinical Research Product Manager, DNASTAR
                                                                Biography
                                                                  Kerri Phillips is a product manager for DNASTAR where she focuses on the needs of the companys clinical research and laboratory customers. Software tools for cancer clinical research must provide efficiencies, support process, and take advantage of an ever growing quantity and variety of data sources. In her role, Kerri helps to bring the end-user perspective into the software development process. Prior to coming to DNASTAR last year, Kerri spent eight years in software development for clinical research administration.
                                                                • Nadya Tarasova, PhD
                                                                  Head, Synthetic Biologics Core, Cancer and Inflammation Program, Center for Cancer Research National Cancer Institute
                                                                  Biography
                                                                    Dr. Tarasova was trained as a bioorganic chemist. She obtained her Ph.D. in chemistry at Lomonosov University, Moscow, Russia in 1981. After post-doctoral training in the lab of Prof. Bent Foltmann at Copenhagen University, Denmark, she established a group working on the chemistry of proteolytic enzymes in the Chemistry Department of Lomonosov University. Dr. Tarasova joined the ABL-Basic Research Program of NCI as Visiting Scientist in 1991 and became a Staff Scientist in NCI Center for Cancer Research in 1999. She was appointed a Head of Synthetic Biologics and Drug Discovery Facility in 2008.
                                                                  Sponsored By

                                                                  For information on becoming a sponsor or exhibitor, please click here.


                                                                  Continuing Education (CME/CE/CEU) Credits

                                                                  The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                                                  Committee

                                                                  To download the Program Committee brochure here.


                                                                  • Alan Wright, MD

                                                                    Dr. Wright is the Chief Medical Officer at Roche Diagnostics Corporation in Indianapolis, Indiana. Prior to joining Roche, Dr. Wright served as Senior Vice President of Health Improvement Strategies for Miraca Life Sciences. He was the Vice President for Product Strategy and ...

                                                                    See more See less
                                                                  • Vincent Mauro, Ph.D.

                                                                    Dr. Mauro is an Associate Professor in the Department of Neurobiology at the Scripps Research Institute in La Jolla, California. He is also a co-founder and lead scientist of Promosome, a biotechnology company focused on bioproduction enablement and DNA vaccines. In addition, Dr ...

                                                                    See more See less
                                                                  • Paul Mathews, PhD

                                                                    Dr. Paul J. Mathews received his bachelors degree from the University of Oregon where he studied invertebrate behavioral plasticity in the lab of Dr. Nathan Tublitz. He received his Ph.D. in neuroscience from the University of Texas at Austin under the mentorship of Dr. Nace ...

                                                                    See more See less
                                                                  • Tatjana Matejic, PhD, D(ABMLI)

                                                                  • Mark Marzinke, PhD, BABCC

                                                                    Mark Marzinke, PhD, DABCC earned a Ph.D. in Biochemistry from the University of Wisconsin-Madison and subsequently completed a clinical chemistry fellowship at The Johns Hopkins University in 2012. During his clinical fellowship, Dr. Marzinke focused on the development and ...

                                                                    See more See less
                                                                  • Alan Maisel, MD

                                                                    Dr. Alan Maisel attended University of Michigan Medical School and did his cardiology training at the University of California at San Diego. He is currently Professor of Medicine at the University and director of the coronary care unit and the heart failure program at the ...

                                                                    See more See less
                                                                  • C Jimmy Lin, MD, PhD, MHS

                                                                    Jimmy Lin, MD, PhD, MHS, is a 2012 TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Partnering with 18 of the top medical ...

                                                                    See more See less
                                                                  • Agnieszka Lichanzka Ph.D.

                                                                    Agnieszka is currently a Staff Scientist and Laboratory Manager at TessArae, LLC in Sterling, VA, USA. She obtained her PhD at the University of Queensland in Australia in a field of biochemistry, and subsequently worked as a post-doctoral fellow at Queen's University of Belfast ...

                                                                    See more See less
                                                                  • Kamisha Johnson-Davis, PhD, DABCC, FACB

                                                                    Dr. Johnson-Davis is a medical director of the Clinical Toxicology laboratory, Antifungal Testing and Immunosuppressants Testing at ARUP. Dr. Johnson-Davis received her PhD in pharmacology at the University of Utah and is board certified in clinical chemistry by the American ...

                                                                    See more See less
                                                                  • Bruce Hollis, PhD

                                                                    Bruce W. Hollis, Ph.D. received his B.Sc. and M.Sc. from the Ohio State University and subsequently his Ph.D. from the University of Guelph in 1979. Dr. Hollis then completed an Endocrine Fellowship at The Case Western Reserve University School of Medicine in 1982. Dr. Hollis ...

                                                                    See more See less
                                                                  • Michael Holick, MD, PhD

                                                                    Michael F. Holick, Ph.D., M.D. is Professor of Medicine, Physiology and Biophysics; Director of the General Clinical Research Unit; and Director of the Bone Health Care Clinic and the Director of the Vitamin D, Skin and Bone Research Laboratory at Boston University Medical ...

                                                                    See more See less
                                                                  • Ross J Molinaro, PhD, MT(ASCP), DABCC, FACB

                                                                    Ross J. Molinaro, PhD, MT(ASCP), DABCC, FACB is an Assistant Professor in the Department of Pathology and Laboratory Medicine at Emory University. He received his PhD in Clinical Chemistry and Molecular Medicine from Cleveland State University and completed the ComACC training ...

                                                                    See more See less
                                                                  • Howard Morris, PhD, FAACB, FFSc(RCPA)

                                                                    Professor Howard Morris is Professor of Medical Sciences at the University of South Australia and a Chief Medical Scientist in Chemical Pathology at SA Pathology, Adelaide, South Australia. He is currently Vice-President of the International Federation of Clinical Chemistry ...

                                                                    See more See less
                                                                  • John Quackenbush, PhD

                                                                    John Quackenbush received his PhD in 1990 in theoretical physics from UCLA working on string theory models. Following two years as a postdoctoral fellow in physics, Dr. Quackenbush applied for and received a Special Emphasis Research Career Award from the National Center for ...

                                                                    See more See less
                                                                  • Stephanie Willerth, PhD

                                                                    Dr. Willerth currently holds a Canada Research Chair in Biomedical Engineering at the University of Victoria where she is dually appointed in the Department of Mechanical Engineering and Division of Medical Sciences. Her research group investigates how to engineer neural tissue ...

                                                                    See more See less
                                                                  • Bart C. Weimer, PhD

                                                                  • Sihe Wang, PhD DABCC FACB

                                                                    Dr. Sihe Wang is Section Head and Medical Director of Clinical Biochemistry and Director of Clinical Biochemistry Fellowship Training Program, Cleveland Clinic, Cleveland, Ohio. He also chairs the clinical chemistry integration effort for the Cleveland Clinic Health System which ...

                                                                    See more See less
                                                                  • Katerina Venderova, PharmD, PhD

                                                                    Dr. Katerina Venderova obtained her master's and doctorate degrees in pharmacy, and her PhD in Toxicology from Charles University in the Czech Republic. She then received a fellowship from the Parkinson Society Canada and pursued her postdoctoral training at Toronto Western ...

                                                                    See more See less
                                                                  • Theral Timpson

                                                                  • Deanne Taylor, MS, PhD

                                                                    Dr. Taylors background is in biophysics, bioinformatics, computational biology and structural biology with emphasis on human genetics and translational medicine. She obtained her Ph.D. in Biophysics from the University of Michigan, Ann Arbor, and completed a postdoctoral ...

                                                                    See more See less
                                                                  • Leigh Anne Swayne, PhD

                                                                  • Joely Straseski, PhD, MS, MT(ASCP), DABCC

                                                                    Dr. Straseski is a medical director of endocrinology at ARUP Laboratories and an assistant professor of pathology at the University of Utah School of Medicine. She received her PhD in pathology and laboratory medicine and a Master's degree in bacteriology from the University of ...

                                                                    See more See less
                                                                  • Ahmad Salehi, MD, PhD

                                                                    Ahmad Salehi, M.D., Ph.D. is a Clinical Associate Professor at the Department of Psychiatry and Behavioral Sciences, Stanford Medical School and the Director of the Translational Laboratory at the VA Palo Alto Health Care System in California. He obtained his MD in Tehran, Iran ...

                                                                    See more See less
                                                                  • Amy K Saenger, PhD, DABCC, FACB

                                                                  • Ulrich Hengst, PhD

                                                                    Dr. Ulrich Hengst studied biochemistry at the Ruhr University Bochum, Germany, and conducted his graduate research at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland, in the group of Prof. Denis Monard. In 2003 he received his PhD from the ...

                                                                    See more See less
                                                                  • Timothy Harris, PhD

                                                                    Since June 2011, Dr. Harris has served as the Senior Vice President of Translational Medicine at Biogen Idec. Dr. Harris has served as the Director of the Advanced Technology Program at SAIC Frederick since 2007 and Chief Technology Officer for SAIC Frederick since 2008. Prior to ...

                                                                    See more See less
                                                                  • Anthony Grace, PhD

                                                                    Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral ...

                                                                    See more See less
                                                                  • Ariel Louwrier PhD

                                                                    Successful Senior Scientific Business Executive with demonstrated expertise growing markets, revenues, product pipelines and expanding technical organizations into new business opportunities. Educational and business management experience in global markets, with quantified ...

                                                                    See more See less
                                                                  • Martin Latterich, PhD

                                                                    The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                                                    See more See less
                                                                  • Fred Russell Kramer, PhD

                                                                  • Daniel Irimia, MD, PhD

                                                                  • Bradley Ford, MD, PhD

                                                                    Bradley Ford received his M.D. and Ph.D. (Physiology and Biophysics) degrees from SUNY Stony Brook, followed by a Clinical Pathology residency and postdoctoral training in basic and clinical microbiology at Washington University in St. Louis. His research interests include ...

                                                                    See more See less
                                                                  • David Carpentieri, MD

                                                                  • Peter Blume-Jensen, MD, PhD

                                                                    Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, and targeted oncology therapeutics drug discovery prior to joining Metamark as CSO in 2010.&nbsp; From 2001 to 2008 Peter was department head at first Serono, US and ...

                                                                    See more See less
                                                                  • Josip Blonder, MD

                                                                    Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI). In 1978, Dr. Blonder received his M.D. at the Rijeka University ...

                                                                    See more See less
                                                                  • Antonio Baines, PhD

                                                                    Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                                                    See more See less
                                                                  • R. Claudio Aguilar, Ph.D.

                                                                    Dr. Aguilar obtained his PhD degree in Immunochemistry from the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. Dr. Aguilar pursued his post-doctoral training at the National institutes of Health in Bethesda, MD in the lab of the well-known cell ...

                                                                    See more See less
                                                                  • Judd Moul, MD, FACS

                                                                    Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of ...

                                                                    See more See less
                                                                  • Kathryn Wellen, PhD

                                                                  • Ottavio Arancio MD, Ph.D

                                                                    Dr. Ottavio Arancio received his Ph.D and M.D. from the University of Pisa (Italy). From 1981 to 1986 he took residency training in Neurology at the University of Verona (Italy). Dr. Arancio has held Faculty appointments at Columbia University, NYU School of Medicine and at ...

                                                                    See more See less
                                                                  • Eric Gluck, MD, JD

                                                                  • Pierre-Antoine Gourraud, PhD, MPH

                                                                    Pierre-Antoine Gourraud is a former student of the Ecole Normale Suprieure de Lyon in France. After receiving an M.P.H. from University Paris XIII in 2002, he got his Ph.D. in Immunogenetic Epidemiology and Public Health from Toulouse University in 2005. He relocated to the ...

                                                                    See more See less
                                                                  • Wieslaw Furmaga, MD

                                                                    Director, Clinical Chemistry Laboratory University Hospital Director, General Laboratory Cancer Treatment Research Center Director, Proteomics Laboratory UTHSC at San Antonio Interim Director, Molecular Laboratory UTHSC at San Antonio Associate Director, Mycology Laboratory UTHSC ...

                                                                    See more See less
                                                                  • George Fritsma, MS, MT

                                                                    George Fritsma is an associate professor in Laboratory Medicine of the Department of Pathology at the University of Alabama at Birmingham. Prof. Fritsma manages www.fritsmafactor.com, "The Fritsma Factor, Your Interactive Hemostasis Resource," a clinical coagulation ...

                                                                    See more See less
                                                                  • Charles Cantor, PhD

                                                                    Dr. Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc., which is a genetics discovery company with tools, information and strategies for determining the medical impact of genes and genetic variations. He is also the founder of SelectX Pharmaceuticals ...

                                                                    See more See less
                                                                  • Cynthia Bowman MD

                                                                    Dr. Cynthia Bowman has been a broad based general pathologist for over 30 years. She graduated with a BA in Chemistry from St. Olaf College, received her MD from Vanderbilt University Medical School, and trained for 6 years at the University of California, San Francisco as a ...

                                                                    See more See less
                                                                  • Joan W Bennett, PhD

                                                                  • Christoph H. Borchers, Ph.D.

                                                                    Dr. Borchers received his B.S., M.S. and Ph.D. from the University of Konstanz, Germany. After his post-doctoral training and employment as a staff scientist at NIEHS/NIH/RTP, NC and he was the director of the Duke - UNC Proteomics Facility and held a faculty position at UNC ...

                                                                    See more See less
                                                                  • Pinar Bayrak-Toydemir, MD, PhD

                                                                    Dr. Bayrak-Toydemir is the medical director of the Molecular Genetics and Genomics Laboratories at ARUP and an associate professor of pathology at the University of Utah School of Medicine. Dr. Bayrak-Toydemir received her MD from the Ankara University School of Medicine in ...

                                                                    See more See less
                                                                  • Szczepan Baran, VMD, MS

                                                                    Dr. Szczepan Baran is the Global Head, Animal Welfare and Compliance Training at Novartis Institutes for Biomedical Research. Dr. Baran received a Bachelor of Science in Pre-Veterinary Medicine from the University of Delaware, a Veterinary Medical Doctoral degree from the ...

                                                                    See more See less
                                                                  • Sharon Geaghan, MD

                                                                    Dr. Geaghan is Chief, Pathology at Lucile Packard Children's Hospital at Stanford, and Co-Director of Clinical Laboratories at Stanford Hospital and Clinics. She also directs the Bass Pediatric Cancer Center Laboratory at the Lucile Packard Hospital; is Director of the Point of ...

                                                                    See more See less
                                                                  Help

                                                                  General LabRoots Questions

                                                                  For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                                                  Contact us

                                                                  Virtual Events and Webinars

                                                                  Supported Configurations

                                                                  • Operating System Internet Explorer Firefox Chrome Safari
                                                                    Vista IE8+ FF10+ Chrome15+
                                                                    Windows 7 IE8+ FF10+ Chrome15+
                                                                    Windows 8 IE10 FF10+ Chrome15+
                                                                    Mac OS X   FF10+ Chrome15+ Safari5.1+
                                                                  • Cookie settings: session cookies enabled
                                                                  • Browser configuration must have JavaScript enabled
                                                                  • Adobe Flash player 10.2 or later

                                                                  To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                                                  Internet Connection

                                                                  • A minimum of 100Kbps is recommended for audio-only events
                                                                  • A minimum of 300Kbps is recommended for speaker on-video events

                                                                  Computer Equipment

                                                                  • Screen Resolution: Minimum 1024x768
                                                                  • Video Card: 65,000 colors minimum
                                                                  • Sound card and speakers (or headphones) for hearing webcast in full format
                                                                  • Audio Card: 16-bit minimum
                                                                  • RAM: 512MB of free RAM

                                                                  Firewall Protocol

                                                                  • HTTP on port 80 or HTTPS on port 443
                                                                  • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                                                  • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                                                  Work-At-Home Attendees

                                                                  • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                                                  For A Seamless Experience

                                                                  When using a mobile device, FREE Mobile Apps are available:

                                                                  - For viewing Webinars:

                                                                  - For viewing Virtual Events

                                                                  Attendee Guide

                                                                  • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                                                  Virtual Event and Webinar Support:

                                                                  Continuing Education (CME/CE) Support

                                                                  Loading Comments...
                                                                  Show Resources